NEWS & VIEWS

Global private equity and venture capital news and research

Posts Tagged ‘pharmaceuticals’

18 July 2014

Biotech startup InflaRx closes Series B round

clinical development Biotech startup InflaRx has closed its Series B round, which reached the “double digit million Euro space.”

18 July 2014

Roka Bioscience raised $60m via Nasdaq IPO

biotech Venture capital-backed molecular diagnostics specialist Roka Bioscience has raised $60m via an IPO on the Nasdaq exchange.

27 June 2014

EMX Capital backs Farmapiel with $28m investment

mexico Mexican private equity fund EMX Capital has agreed to invest up to MXN370m ($28m) in pharmaceutical company Farmapiel.

24 June 2014

Carlyle invests in Sunsho Pharmaceutical from third Japanese fund

fujiyama Private equity major Carlyle has bought Japanese health and nutrition (H&N) and pharmaceutical products maker Sunsho Pharmaceutical.

23 June 2014

Luye Pharma’s private equity backers look to raise $761m via Hong Kong IPO

hong kong The private equity backers of Luye Pharma Group are reportedly looking to raise as much as HK$5.9bn ($761m) in the IPO of the Chinese drug maker.

4 June 2014

TPG Biotech leads $25m Series B for Trevi Therapeutics

medical monitor Biotech startup Trevi Therapeutics has raised a $25m Series B round led by TPG's life sciences vemnture investment arm TPG Biotech.

30 May 2014

GSK looks to sell older drugs to buyout firms

meddd GlaxoSmithKline is reportedly looking to sell a range of its older drugs to private equity firms.

27 May 2014

Wellington Partners leads €2.7m Series A for Germany’s Neuway Pharma

german flag 2_sq Venture capital firm Wellington Partners has led a €2.7m Series A round for German pharmaceutical startup Neuway Pharma.

23 April 2014

Kala Pharmaceuticals scores $22.5m Series B

dollar envelope money Ysios Capital has led a $22.5m Series B round for Kala Pharmaceuticals, which is focused on developing ophthalmic products based on its mucus penetrating particle technology.

15 April 2014

Column Group nears $200m mark for second fund

biotech_lrg Biotech-focused investment firm The Column Group has passed the halfway mark for its $250m-targeting second venture capital fund, according to documents filed with US securities regulators.

Page 1 of 512345

Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014